Faron Pharmaceuticals Oy, a clinical-stage biopharmaceutical company, has announced its intention to raise approximately EUR 30.7 million through a proposed retail offer via the Retail Capital Markets 'REX' portal. The offering will include the issuance of up to 30,714,592 Ordinary Shares at a subscription price of EUR 1 per Offer Share. The REX Offer is part of a larger Offering, which also includes a Public Offering, an Institutional Offering, and a UK Open Offer.
The REX Offer will be open to eligible investors in the United Kingdom and is expected to close at or around 7:30 a.m. on 19 June 2024. Interested investors can participate through certain financial intermediaries, such as AJ Bell and interactive investor. The minimum subscription is 50 per investor, and the Company reserves the right to scale back any order or reject any application for subscription under the REX Offer.
The Company values its retail shareholder base in the United Kingdom and believes that it is appropriate to provide retail investors in the United Kingdom the opportunity to participate in the current fundraising. The REX Offer is conditional upon the completion of the Public Offering, Institutional Offering, and the UK Open Offer, as well as the Admission of the REX Offer Shares to trading on AIM and Nasdaq First North Growth Market Finland of Nasdaq Helsinki Ltd, which is expected to take place at or around 8:00 a.m. on 24 June 2024.
Investors interested in participating in the REX Offer should contact their broker or wealth manager. The terms and conditions on which investors subscribe will be provided by the relevant financial intermediaries, including relevant commission or fee charges. The Company has emphasized that the REX Offer is not part of the Public Offering, Institutional Offering, or the UK Open Offer.
This announcement serves as a financial promotion and is not intended to be investment advice. It has been approved by Peel Hunt LLP, which is authorized and regulated by the Financial Conduct Authority. Interested retail brokers wishing to participate in the REX Offer on behalf of retail investors should contact [email protected].